Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.
์ข
๋ชฉ ์ฝ๋ RGNT
ํ์ฌ ์ด๋ฆRegentis Biomaterials Ltd
์์ฅ์ผDec 04, 2025
CEOHazum (Eli)
์ง์ ์- -
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃ- -
์ฃผ์60, Medinat Hyahudim
๋์HERZLIYA
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX โ NASDAQ Basic Amex
๊ตญ๊ฐIsrael
์ฐํธ ๋ฒํธ4676652
์ ํ97246265502
์น์ฌ์ดํธhttps://www.regentis.co.il/
์ข
๋ชฉ ์ฝ๋ RGNT
์์ฅ์ผDec 04, 2025
CEOHazum (Eli)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์